Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. PARTICIPANTS: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have reported that 44-62% of cases experience a reversal of hypogonadism, usually within 6 months after starting treatment (225,226).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [226]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Persistently elevated prolactin levels can indicate the presence of pituitary tumors, such as prolactinomas”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“development and implementation of evidence-based guidelines (1).”
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
Self-citationHigh Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationAdvances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
A Radioimmunoassay for Human Prolactin
Hwang, P., Guyda, H., & Friesen, H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1902 · Cited by 752 · cited 2×
“1970 permitted development of RIAs (4, 5), which en-”
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Cited by
Items 301–400 of 1,001
Williamson, C., & Scott, R. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198851899.003.0005 · Cited by 32
Hypothalamic Control of Prolactin Secretion, and the Multiple Reproductive Functions of Prolactin
Grattan, D. R., & Tissier, P. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397175-3.00012-0 · Cited by 39
Contemporary Management of Male Infertility
Stahl, P. J., Stember, D. S., & Goldstein, M. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-051810-101036 · Cited by 36
MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas
Micko, A. S. G., Wöehrer, A., Höftberger, R., Vila, G., Marosi, C., Knosp, E., & Wolfsberger, S. (2017) · Pituitary · doi:10.1007/s11102-017-0829-3 · Cited by 31
Ahmad, J., Priya, D., & Akhtar, N. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.159058 · Cited by 31
“• As per WHO guidelines, PRL level > 25 μg/l is considered as hyperprolactinemia.[9]”
BackgroundHow and when to use temozolomide to treat aggressive pituitary tumours
Whitelaw, B. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0083 · Cited by 30
Rusgis, M. M., Alabbasi, A., & Nelson, L. A. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab065 · Cited by 36
“aripiprazole, dopamine agonists, metformin, or herbal supplements to the antipsychotic regimen.(16,20-22) This article reviews management options for antipsychotic-induced hyperprolactinemia and associated treatment considerations such as efficacy, tolerability, drug interactions, contraindications, and dosing regimen…”
BackgroundInfluentialManagement of macroprolactinomas
Tirosh, A., & Shimon, I. (2015) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-015-0006-4 · Cited by 33
“Cystic prolactinoma is a unique entity, which usually does not shrink enough under DA treatment and surgery should be considered in invasive cases [6, 9, 10].”
BackgroundInfluentialCastro, M. A., Biagetti, B., Torre, E. L. M., Novoa-Testa, I., Cordido, F., Corrales, E. P., Berrocal, V. R., Guerrero‐Pérez, F., Vicente, A., Percovich, J. C., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae126 · Cited by 29
Genomic Characterization of Human and Rat Prolactinomas
Tong, Y., Zheng, Y., Zhou, J. R., Oyesiku, N. M., Koeffler, H. P., & Melmed, S. K. (2012) · Endocrinology · doi:10.1210/en.2012-1056 · Cited by 32
“reducing both prolactin levels and tumor volume (1).”
BackgroundSelf-citationNeto, L. V., Boguszewski, C. L., de Araújo, L. A., Bronstein, M. D., Miranda, P. A. C., Musolino, N. R. D. C., Naves, L. A., Vilar, L., Ribeiro‐Oliveira, A., & Gadelha, M. R. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000179 · Cited by 37
“Thus, in patients with macroadenoma, especially those > 3 cm and with normal or not so elevated prolactin values, a new dosage after a prolactin serum dilution of 1:100 must be obligatorily performed to distinguish prolactinoma from NFPA (34,37,38).”
BackgroundRecent Progress in the Medical Therapy of Pituitary Tumors
Langlois, F., McCartney, S., & Fleseriu, M. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.2.162 · Cited by 34
Aggressive and Malignant Prolactinomas
Olarescu, N. C., Perez‐Rivas, L. G., Gatto, F., Cuny, T., Tichomirowa, M. A., Tamagno, G., & Gahete, M. D. (2019) · Neuroendocrinology · doi:10.1159/000497205 · Cited by 31
Manojlović-Gačić, E., Bollerslev, J., & Casar‐Borota, O. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12568 · Cited by 29
Matalliotakis, M., Koliarakis, I., Matalliotaki, C., Trivli, A., & Hatzidaki, E. (2019) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v90i1.8142 · Cited by 29
“According to current formal guidelines, discontinuation of DA therapy is indicated after ≥2 years of treatment, normal prolactin levels, and no MRI image of pituitary adenoma (14).”
BackgroundOATP1A2 and OATP2B1 Are Interacting with Dopamine-Receptor Agonists and Antagonists
Schäfer, A. M., zu Schwabedissen, H. E. M., Bien-Möller, S., Hubeny, A., Vogelgesang, S., Oswald, S., & Grube, M. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00159 · Cited by 29
Omar, A. T., Muñoz, D. G., Goguen, J., Lee, J. M., Rotondo, F., Kovács, K., & Cusimano, M. D. (2020) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2020.106306 · Cited by 31
Pre-operative serum inflammation-based scores in patients with pituitary adenomas
Marques, P., de Vries, F., Dekkers, O. M., van Furth, W. R., Korbonits, M., Biermasz, N. R., & Pereira, A. M. (2020) · Pituitary · doi:10.1007/s11102-020-01112-5 · Cited by 34
Beccuti, G., Guaraldi, F., Natta, G., Cambria, V., Prencipe, N., Cicolin, A., Montanaro, E., Lopiano, L., Ghigo, E., Zibetti, M., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01478-0 · Cited by 33
Clinical and radiological findings in macroprolactinemia
Işık, S., Berker, D. S., Tütüncü, Y., Özuğuz, U., Gökay, F., Erden, G., Özcan, H. N., Küçükler, F. K., Aydın, Y., & Güler, S. (2011) · Endocrine · doi:10.1007/s12020-011-9576-9 · Cited by 29
Harrington, M. H., & Casella, S. J. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32834ed6b9 · Cited by 31
“Although recommendations from an Endocrine Society Clinical Practice guideline were recently published on the diagnosis and treatment of hyperprolactinemia, including the preference for use of cabergoline over other dopamine agonists, management in children was not specifically addressed [27].”
BackgroundPituitary disorders in pregnancy
Chrisoulidou, A., Boudina, M., Karavitaki, N., Bill, E., & Wass, J. A. H. (2015) · HORMONES · doi:10.1007/bf03401382 · Cited by 31
Self-citationThe current state of MRI-based radiomics in pituitary adenoma: promising but challenging
Zheng, B., Zhao, Z. W., Zheng, P., Liu, Q., Li, S., Jiang, X., Huang, X., Ye, Y., & Wang, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1426781 · Cited by 38
Byberg, S., Futtrup, J., Andreassen, M., & Krogh, J. (2019) · Endocrine Connections · doi:10.1530/ec-19-0286 · Cited by 31
Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor
Lin, A. L., Donoghue, M. T. A., Wardlaw, S. L., Yang, J. T., Bodei, L., Tabar, V. S., & Geer, E. B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa649 · Cited by 31
Functions of Membrane Progesterone Receptors (mPRs, PAQRs) in Nonreproductive Tissues
Thomas, P., Pang, Y., Camilletti, M. A., & Castelnovo, L. F. (2022) · Endocrinology · doi:10.1210/endocr/bqac147 · Cited by 32
Macroprolactin: searching for a needle in a haystack?
Lippi, G., & Plebani, M. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1283 · Cited by 28
“Finally, we wish that this paper, along with other contributions, should add fuel to the request to update and improve the current version of the Clinical Practice Guideline on the Diagnosis and Treatment of Hyperprolactinemia, and in particular the section of the guideline dealing with the biochemical diagnosis of hy…”
BackgroundGrzywotz, A., Kleist, B., Möller, L. C., Hans, V., Göricke, S. L., Sure, U., Müller, O., & Kreitschmann‐Andermahr, I. (2017) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2017.10.006 · Cited by 30
Endocrine and metabolic assessment in adults with Langerhans cell histiocytosis
Montefusco, L. B., Harari, S. A., Elia, D., Rossi, A., Specchia, C., Torre, O., Adda, G., & Arosio, M. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.11.011 · Cited by 31
“PRL values were obtained after 60 min of saline infusion with patient in rest position and considered normal if< 25 ng/mL in women and< 20 ng/mL in men [40].”
MethodThe value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome
Kyritsi, E. M., Dimitriadis, G. K., Angelousi, A. G., Mehta, H., Shad, A., Mytilinaiou, M. G., Kaltsas, G., & Randeva, H. S. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12961 · Cited by 31
Feasibility, safety, and outcomes of a stratified fast-track care trajectory in pituitary surgery
Lobatto, D. J., Vlieland, T. P. M. V., van den Hout, W. B., de Vries, F., de Vries, A. F., Schutte, P. J., Verstegen, M. J. T., Pereira, A. M., Peul, W. C., Biermasz, N. R., et al. (2020) · Endocrine · doi:10.1007/s12020-020-02308-2 · Cited by 31
Opioids and pituitary function: expert opinion
Gadelha, M. R., Karavitaki, N., Fudin, J., Bettinger, J. J., Raff, H., & Ben-Shlomo, A. (2022) · Pituitary · doi:10.1007/s11102-021-01202-y · Cited by 27
Rivero, J. D., Gangi, A., Annes, J. P., Jasim, S., Keller, J., Lundholm, M. D., Silverstein, J. M., Vaghaiwalla, T. M., & Wermers, R. A. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.02.001 · Cited by 36
AACE/ACE Disease State Clinical Review: Medical Management of Cushing Disease
Hamrahian, A. H., Yuen, K. C. J., & Hoffman, A. R. (2014) · Endocrine Practice · doi:10.4158/ep14147.ra · Cited by 27
Self-citationAccuracy of microcystic aspect on T2‐weighted MRI for the diagnosis of silent corticotroph adenomas
Kasuki, L., Antunes, X. L. D. S., Coelho, M. C. A., Lamback, E. B., Galvão, S., Camacho, A. H. S., Chimelli, L. M. C., Ventura, N., & Gadelha, M. R. (2019) · Clinical Endocrinology · doi:10.1111/cen.14133 · Cited by 27
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
Pivonello, C., Patalano, R., Negri, M., Pirchio, R., Colao, A. A. L., Pivonello, R., & Auriemma, R. S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.791633 · Cited by 31
Działach, Ł., Sobolewska, J., Żak, Z., Respondek, W., & Witek, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1338345 · Cited by 39
Cuny, T., Mohamed, A., Graillon, T., Roche, C., Defilles, C., Germanetti, A. L., Couderc, B. C., Figarella‐Branger, D., Enjalbert, A., Barlier, A., et al. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.01.026 · Cited by 27
“Nevertheless, between 10% and 20% of prolactinomas are resistant to DA, defined as failure to normalize PRL levels and reduce tumor size (Melmed et al., 2011; Molitch, 2005).”
BackgroundCai, L., Leng, Z. G., Guo, Y., Lin, S., Wu, Z. R., Su, Z. P., Lu, J. L., Wei, L. F., Zhuge, Q. C., Jin, K., et al. (2015) · Endocrine · doi:10.1007/s12020-015-0824-2 · Cited by 26
Designing and evaluating autoverification rules for thyroid function profiles and sex hormone tests
Li, J., Cheng, B., Ouyang, H., Xiao, T., Hu, J., & Cai, Y. (2017) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563217712291 · Cited by 27
O’Sullivan, S., Farrant, M. T., Ogilvie, M., Gunn, A. J., & Milsom, S. R. (2019) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13070 · Cited by 27
Prolactinomas and menopause: any changes in management?
Greenman, Y. (2019) · Pituitary · doi:10.1007/s11102-019-00998-0 · Cited by 30
Is there a role for early chemotherapy in the management of pituitary adenomas?
Lin, A. L., Sum, M., & DeAngelis, L. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now059 · Cited by 31
“Serum PRL is not normalized in 10%–20% of patients with prolactinomas who are treated with cabergoline.(60) An elevated PRL level is not an immediate indication for a change in treatment.”
BackgroundPituitary Disorders in Pregnancy
Woodmansee, W. W. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.09.009 · Cited by 33
Biochemical diagnosis in prolactinomas: some caveats
Petersenn, S. (2019) · Pituitary · doi:10.1007/s11102-019-01024-z · Cited by 28
Do nothing but observe microprolactinomas: when and how to replace sex hormones?
Bonert, V. S. (2020) · Pituitary · doi:10.1007/s11102-020-01039-x · Cited by 44
Andersen, I. B., Andreassen, M., & Krogh, J. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14183 · Cited by 28
“It is notable that cabergoline is probably as efficient as bromocriptine as an antiglycaemic agent, because cabergoline is less expensive and is known to have fewer adverse events than bromocriptine,(44) thus cabergoline is the first choice in the treatment of hyperprolactinaemia.(45) Although we found a moderate effe…”
BackgroundCirculating prolactin level is increased in metabolically healthy obesity
Liu, J., Zhang, L., Fu, J. H., Wang, Q., & Wang, G. (2021) · Endocrine Connections · doi:10.1530/ec-21-0040 · Cited by 30
Drug resistance in pituitary tumours: from cell membrane to intracellular signalling
Peverelli, E., Treppiedi, D., Mangili, F., Catalano, R., Spada, A., & Mantovani, G. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00514-0 · Cited by 30
Andereggen, L., Frey, J., Andres, R. H., Luedi, M. M., Gralla, J., Schubert, G. A., Beck, J., Mariani, L., & Christ, E. (2021) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2021.100258 · Cited by 31
“The upper limit of the PRL level was 25 μg/L for women and 20 μg/L for men [24].”
BackgroundSurgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis
Yagnik, K. J., Erickson, D. Z., Bancos, I., Atkinson, J. L. D., Choby, G. W., Peris‐Celda, M., & Gompel, J. J. V. (2021) · Pituitary · doi:10.1007/s11102-021-01188-7 · Cited by 28
Bakker, L. E. H., Verstegen, M. J. T., Ghariq, E., Verbist, B. M., Schutte, P. J., Bashari, W. A., Kruit, M. C., Pereira, A. M., Gurnell, M., Biermasz, N. R., et al. (2022) · Pituitary · doi:10.1007/s11102-022-01230-2 · Cited by 26
Iacovazzo, D., Bianchi, A., Lugli, F., Milardi, D., Giampietro, A., Cordisco, E. L., Doglietto, F., Lauriola, L., & Marinis, L. D. (2013) · Endocrine · doi:10.1007/s12020-013-9876-3 · Cited by 26
Barake, M., Klibanski, A., & Tritos, N. A. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0667 · Cited by 30
Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts
Gao, J., Liu, Y., Han, G., Deng, K., Liu, X., Bao, X., Feng, M., Yao, Y., Lian, W., Xing, B., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13963 · Cited by 26
“Treatment with dopamine agonists is currently the first choice for PRLomas because they can normalize PRL levels, reduce the volume of tumour, and restore gonadal function.(18,19) Reportedly, however, about 25% of patients are resistant to BC, and 10% are resistant to cabergoline.”
BackgroundManagement of cystic prolactinomas: a review
Nakhleh, A., Shehadeh, N., Hochberg, I., Zloczower, M., Zolotov, S., Taher, R., & Naccache, D. D. (2018) · Pituitary · doi:10.1007/s11102-018-0888-0 · Cited by 26
Clinical characteristics and surgical outcome of prolactinoma in patients under 14 years old
Zhao, Y., Jin, D., Lian, W., Xing, B., Feng, M., Liu, X., & Wang, R. (2019) · Medicine · doi:10.1097/md.0000000000014380 · Cited by 25
“For patients with PRL level under 200ng/mL, diagnosis should be made with consideration on clinical presentation and sellar MRI.([6]) In patients with no indication for emergency operation (acute pituitary apoplexy, rapid progress of vision loss, leakage of cerebrospinal fluid) or drug resistant, medical therapy of do…”
BackgroundInfluentialPituitary incidentalomas: A guide to assessment, treatment and follow-up
Paschou, S. Α., Vryonidou, A., & Goulis, D. G. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.08.006 · Cited by 27
Prolactin concentration in various stages of endometriosis in infertile women
Mirabi, P., Alamolhoda, S. H., Golsorkhtabaramiri, M., Namdari, M., & Esmaeilzadeh, S. (2019) · JBRA Assisted Reproduction · doi:10.5935/1518-0557.20190020 · Cited by 25
“PRL secretion was deemed normal when baseline serum levels were 25ng/ml or lower at least two hours after waking up in the morning (Melmed et al., 2011).”
BackgroundMachine Learning for Outcome Prediction in First-Line Surgery of Prolactinomas
Huber, M., Luedi, M. M., Schubert, G. A., Musahl, C., Tortora, A., Frey, J., Beck, J., Mariani, L., Christ, E., & Andereggen, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.810219 · Cited by 25
“Upper limits of >20 ng/mL were de fi ned as hyperprolactinemia (33).”
BackgroundCancela, A. A., Berrocal, V. R., Arias, H. P., Díez, J. J., & Iglesias, P. (2022) · Endocrine · doi:10.1007/s12020-022-03161-1 · Cited by 25
Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment
Shimon, I. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.102883 · Cited by 30
CEBPD Suppresses Prolactin Expression and Prolactinoma Cell Proliferation
Tong, Y., Zhou, J. R., Mizutani, J., Fukuoka, H., Ren, S.-G., Gutierrez‐Hartmann, A., Koeffler, H. P., & Melmed, S. K. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-1075 · Cited by 25
Self-citationVilar, L., Albuquerque, J. L., Gadelha, P. S., Filho, F. R., Siqueira, A. M. C., da Fonseca, M. M., Viana, K. F., Gomes, B. S., & Lyra, R. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00011 · Cited by 25
Role of gamma knife radiosurgery in the treatment of prolactinomas
Ježková, J., Hána, V., Kosák, M., Kršek, M., Liščák, R., Vymazal, J., Pecen, L., & Marek, J. (2019) · Pituitary · doi:10.1007/s11102-019-00971-x · Cited by 25
Melson, E., Davitadze, M., Aftab, M., Ng, C. Y., Ooi, E., Blaggan, P., Chen, W., Hanania, T., Thomas, L., Zhou, D., et al. (2020) · BMC Medical Education · doi:10.1186/s12909-020-02190-6 · Cited by 28
Management of hyperprolactinemic infertility
Crosignani, P. G. (2012) · Middle East Fertility Society Journal · doi:10.1016/j.mefs.2012.04.003 · Cited by 25
Long-term outcome of multimodal therapy for giant prolactinomas
Andújar-Plata, P., Villar‐Taibo, R., Ballesteros-Pomar, M. D., Vidal‐Casariego, A., Pérez-Corral, B., Cabezas-Agrícola, J. M., Álvarez-Vázquez, P., Serramito-García, R., & Bernabéu, I. (2016) · Endocrine · doi:10.1007/s12020-016-1129-9 · Cited by 24
Shahrestani, S., Cardinal, T. M., Micko, A. S. G., Strickland, B. A., Pangal, D. J., Kugener, G., Weiss, M. H., Carmichael, J. D., & Zada, G. (2021) · Pituitary · doi:10.1007/s11102-021-01128-5 · Cited by 24
Wright, K. E., Lee, M., Escobar, N., Pacione, D. R., Young, M., Fatterpekar, G. M., & Agrawal, N. (2021) · Endocrine · doi:10.1007/s12020-021-02744-8 · Cited by 24
“prolactinoma, particularly in macroadenomas (>1 cm) [6].”
BackgroundA Meta-Analysis of Observational Studies on Prolactin Levels in Women with Polycystic Ovary Syndrome
Naz, M. S. G., Mousavi, M. A., Mahboobifard, F., Niknam, A., & Tehrani, F. R. (2022) · Diagnostics · doi:10.3390/diagnostics12122924 · Cited by 37
Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects
Mastnak, L., Herman, R., Ferjan, S., Janež, A., & Jensterle, M. (2023) · Life · doi:10.3390/life13112124 · Cited by 40
“PCOS is categorized as a potential etiology of HPRL [63].”
BackgroundHamblin, R., & Karavitaki, N. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.102910 · Cited by 27
Genetics of pituitary adenomas
Korbonits, M., & Shaid, M. (2017) · Neurology India · doi:10.4103/neuroindia.ni_330_17 · Cited by 24
Ospina, N. S., Rodríguez‐Gutiérrez, R., Brito, J. P., Young, W. F., & Montori, V. M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0435-z · Cited by 28
Self-citationManagement of Polycystic Ovary Syndrome in India
Malik, S., Jain, K., Talwar, P., Prasad, S., Dhorepatil, B., Devi, G., Khurana, A., Bhatia, V., Chandiok, N., Kriplani, A., et al. (2014) · Fertility Science and Research · doi:10.4103/2394-4285.146798 · Cited by 43
The safety of treatments for prolactinomas
Auriemma, R. S., Grasso, L. F. S., Pivonello, R., & Colao, A. A. L. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1151493 · Cited by 24
Management of prolactinomas: a survey of physicians from the Middle East and North Africa
Beshyah, S., Sherif, I., Chentli, F., Hamrahian, A. H., Khalil, A., Raef, H., El-Fiki, M. E., & Jambart, S. (2016) · Pituitary · doi:10.1007/s11102-016-0767-5 · Cited by 24
“Despite the best practice recommendations from professional endocrine societies reflecting the evidence-base and expert opinion [4, 5], there are still several areas of controversies in the management (both diagnosis and treatment).”
BackgroundResultInfluentialSurgical indications for pituitary tumors during pregnancy: a literature review
Graillon, T., Cuny, T., Castinetti, F., Courbière, B., Cousin, M., Albarel, F., Morange, I., Bruder, N. J., Brue, T. C., & Dufour, H. (2019) · Pituitary · doi:10.1007/s11102-019-01004-3 · Cited by 27
Predictors of the Response to Dopaminergic Therapy in Patients With Prolactinoma
Hage, C., & Salvatori, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa652 · Cited by 24
Castro, M. A., Corrales, E. P., Millán, J. M. S., Rebolleda, G., Pian, H. G., Ruz‐Caracuel, I., Santos, G. D. L., Urzaiz, L. L., Escobar-Morreale, H. F., & Berrocal, V. R. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.11.001 · Cited by 26
Basic endocrinological disorders in chronic renal failure.
Niemczyk, S., Niemczyk, L., & Romejko, K. (2012) · PubMed · Cited by 38
Jiang, X.-B., He, D., Mao, Z.-G., Fan, X., Lei, N., Hu, B., Song, B., Zhu, Y., & Wang, H. (2013) · Tumor Biology · doi:10.1007/s13277-013-0660-z · Cited by 24
“Prolactinomas account for 40 % of pituitary adenomas, with a prevalence as high as 45 per 71,000 inhabitants [1, 2].”
BackgroundRadiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure
Akinduro, O. O., Lu, V. M., Izzo, A., Biase, G. D., Vilanilam, G. K., Gompel, J. J. V., Bernet, V. J., Donaldson, A. M., Olomu, O. U., Meyer, F. B., et al. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.05.249 · Cited by 23
Li, C., Zhu, H., Zong, X., Wang, X., Gui, S., Zhao, P., Bai, J., Liu, C., Cao, L., Li, Z., et al. (2020) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2020.106176 · Cited by 23
Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors
Mattogno, P. P., D’Alessandris, Q. G., Chiloiro, S., Bianchi, A., Giampietro, A., Pontecorvi, A., Marinis, L. D., Olivi, A., Anile, C., & Lauretti, L. (2021) · Cancers · doi:10.3390/cancers13133252 · Cited by 23
Leca, B. M., Mytilinaiou, M. G., Tsoli, M., Epure, A., Aylwin, S. J. B., Kaltsas, G., Randeva, H. S., & Dimitriadis, G. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-89256-7 · Cited by 23
Zhang, L., Qi, H., Xie, Y., Zheng, W., Liu, X., Cai, D.-B., Ng, C. H., Ungvari, G. S., & Xiang, Y. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.728204 · Cited by 28
“The normal plasma level of prolactin is below 25 ng/ml for women and below 20 ng/ml for men, and HPRL refers to sustained prolactin levels above normal (3).”
BackgroundForce, B. K., Staggers, K. A., Sebastian, S., Takashima, M., Yoshor, D., & Samson, S. L. (2022) · World Neurosurgery · doi:10.1016/j.wneu.2022.10.043 · Cited by 23
M ultiple endocrine neoplasia type 1 ( MEN1 )
Carroll, R. W. (2012) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12046 · Cited by 31
Symptomatic Rathke's cleft cyst with a co-existing pituitary tumor; Brief review of the literature
Babu, R., Back, A. G., Komisarow, J. M., Owens, T. R., Cummings, T. J., & Britz, G. W. (2013) · Asian Journal of Neurosurgery · doi:10.4103/1793-5482.125662 · Cited by 23
“This presents with galactorrhea, amenorrhea and hypogonadism.([33]) However, the cause of this hyperprolactinemia may be unclear when a pituitary mass is present as it may also be due to a prolactin-secreting adenoma.”
BackgroundBehnaz, M., Majd, Z., Radfar, M., Ajami, H., Qorbani, M., & Kokab, A. (2017) · Spinal Cord · doi:10.1038/sc.2017.73 · Cited by 25
65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update
Syro, L. V., Rotondo, F., Ortiz, L. D., & Kovács, K. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0015 · Cited by 23
Balijepalli, C., Druyts, E., Zoratti, M. J., Wu, P., Kanji, S., Rabheru, K., Yan, K., & Thorlund, K. (2018) · Schizophrenia Research and Treatment · doi:10.1155/2018/1543034 · Cited by 28
Pekić, S., Medic‐Stojanoska, M., & POPOVIC, V. M. (2018) · Neuroendocrinology · doi:10.1159/000494725 · Cited by 24
A Century of Prolactin: Emerging Perspectives as a Metabolic Regulator
Wu, T., Duan, Y., Jiang, J., Gu, T., Zhang, P., & Bi, Y. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3836 · Cited by 29
“Pathological hyperprolactinaemia, characterised by a prolactin level > 100 μg/L, is primarily caused by prolactinoma, ectopic prolactin secretion, and chronic kidney diseases [31].”
Optimizing laboratory defined macroprolactin algorithm
Šoštarić, M., Bokulić, A., Marijančević, D., & Zec, I. (2019) · Biochemia Medica · doi:10.11613/bm.2019.020706 · Cited by 23
“The Endocrine Society guidelines recommend screening for macroprolactin in all asymptomatic patients with elevated prolactin concentrations (12).”
BackgroundImmunomodulating Effects Depend on Prolactin Levels in Patients with Hyperprolactinemia
Ernerudh, J., Wahlberg, J., Ewerman, L., Landberg, E., Hellberg, S., Hovland, M., Sundin, A., Jenmalm, M. C., & Ekman, B. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1126-4272 · Cited by 28
“Elevated prolactin levels can also be caused by medications, renal and liver failure, hypothyroidism or a prolactinoma, which is the most common type of hormone-secreting pituitary adenoma [2].”
BackgroundMangili, F., Giardino, E., Treppiedi, D., Barbieri, A. M., Catalano, R., Locatelli, M., Lania, A. G., Spada, A., Arosio, M., Mantovani, G., et al. (2020) · Neuroendocrinology · doi:10.1159/000509219 · Cited by 22
Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas
Park, J. Y., Choi, W., Hong, A. R., Yoon, J. H., Kim, H. K., Jang, W., Jung, S., & Kang, H. (2021) · Pituitary · doi:10.1007/s11102-021-01168-x · Cited by 22
Metadata
- Authors
- Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Universidade de Santiago de Compostela (ES)
- VA Palo Alto Health Care System (US)
- New York University (US)
- University of Iowa (US)
- Churchill Hospital (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02
- Volume
- 96
- Issue
- 2
- Pages
- 273-288
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2019055295
- Semantic Scholar
- 43454263bc46394124a75b19ce2b73452ff5e993
- Cited by
- 1,844
- References
- 141
- Citations by year
- 2026: 133 · 2025: 125 · 2024: 141 · 2023: 150 · 2022: 186 · 2021: 170 · 2020: 138 · 2019: 148 · 2018: 103 · 2017: 107 · 2016: 102 · 2015: 97 · 2014: 76 · 2013: 66 · 2012: 71
- FWCI
- 61.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Funders
- U.S. Department of Defense
- Eli Lilly and Company
- Pfizer
- Teva Pharmaceutical Industries
- European Society of Endocrinology
- Novo Nordisk
- Ipsen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- hyperprolactinemia, prolactinoma, drug-induced hyperprolactinemia, prolactinoma treatment, pregnancy
- MeSH terms
- Adult, Female, Humans, Hyperprolactinemia, Pituitary Neoplasms, Pregnancy, Prolactinoma, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.